- Home
- TLSA vs LRE Comparison
TLSA vs LRE Comparison
Compare TLSA & LRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- LRE
- Stock Information
- Founded
- TLSA 2013
- LRE 2001
- Country
- TLSA United Kingdom
- LRE Japan
- Employees
- TLSA 9
- LRE N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- LRE
- Sector
- TLSA Health Care
- LRE
- Exchange
- TLSA Nasdaq
- LRE Nasdaq
- Market Cap
- TLSA 187.0M
- LRE 17.6M
- IPO Year
- TLSA 2000
- LRE 2023
- Fundamental
- Price
- TLSA $1.50
- LRE N/A
- Analyst Decision
- TLSA
- LRE
- Analyst Count
- TLSA 0
- LRE 0
- Target Price
- TLSA N/A
- LRE N/A
- AVG Volume (30 Days)
- TLSA 260.9K
- LRE 14.8K
- Earning Date
- TLSA 07-15-2025
- LRE 01-01-0001
- Dividend Yield
- TLSA N/A
- LRE N/A
- EPS Growth
- TLSA N/A
- LRE N/A
- EPS
- TLSA N/A
- LRE N/A
- Revenue
- TLSA N/A
- LRE $110,330,328.00
- Revenue This Year
- TLSA N/A
- LRE N/A
- Revenue Next Year
- TLSA N/A
- LRE N/A
- P/E Ratio
- TLSA N/A
- LRE N/A
- Revenue Growth
- TLSA N/A
- LRE 8.82
- 52 Week Low
- TLSA $0.63
- LRE $1.10
- 52 Week High
- TLSA $1.91
- LRE $2.49
- Technical
- Relative Strength Index (RSI)
- TLSA 48.99
- LRE 57.65
- Support Level
- TLSA $1.53
- LRE $1.71
- Resistance Level
- TLSA $1.81
- LRE $2.11
- Average True Range (ATR)
- TLSA 0.11
- LRE 0.12
- MACD
- TLSA -0.01
- LRE -0.01
- Stochastic Oscillator
- TLSA 11.76
- LRE 34.69
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.